SummaryBaclofen, sold under the brand name Lioresal among others, is a medication used to treat muscle spasticity such as from a spinal cord injury or multiple sclerosis. It may also be used for hiccups and muscle spasms near the end of life. It is taken by mouth or by delivery into the spinal canal. Common side effects include sleepiness, weakness, and dizziness. Serious side effects may occur if baclofen is rapidly stopped including seizures and rhabdomyolysis. Use in pregnancy is of unclear safety while use during breastfeeding is probably safe. It is believed to work by decreasing levels of certain neurotransmitters. Baclofen was approved for medical use in the United States in 1977. It is available as a generic medication. |
Drug Type Small molecule drug |
Synonyms (+-)-Baclofen, 4-Amino-3-(4-chlorophenyl)butyric acid, Baclofen (JP17/USP/INN) + [24] |
Target |
Action agonists |
Mechanism GABAB receptor agonists(Gamma-Aminobutyric Acid B Receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (22 Nov 1977), |
RegulationOrphan Drug (United States), Priority Review (China), Orphan Drug (Japan) |
Molecular FormulaC10H12ClNO2 |
InChIKeyKPYSYYIEGFHWSV-UHFFFAOYSA-N |
CAS Registry1134-47-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Spinal Cord Diseases | United States | 18 Sep 2019 | |
Spinal Cord Injuries | United States | 18 Sep 2019 | |
Hereditary Spastic Paralysis, Infantile Onset Ascending | Japan | 11 Apr 2005 | |
Multiple Sclerosis | United States | 30 Oct 2003 | |
Muscle Spasticity | United States | 17 Jun 1992 | |
Spastic paralysis | Japan | 27 Aug 1979 | |
Spastic paralysis | Japan | 27 Aug 1979 | |
Spasm | United States | 22 Nov 1977 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alcoholism | Phase 3 | France | 01 Dec 2012 |
Not Applicable | 1 | kwwpzwthwi(sftcsphqex) = jsgzboechj ietxlkytdu (oeguowssiq ) | - | 07 Apr 2025 | |||
Phase 4 | 16 | elovfyoihu = pwlhdaxaqn qyolhtlemx (xngujctdui, kzztnjuuew - ykfdulgzka) View more | - | 18 Nov 2024 | |||
Phase 4 | 34 | (Opioid Tolerant - Baclofen) | fshjnkpaip(luemexqqic) = bsdvdokgse fgflcsyqcj (qqxjzjlcnh, 33.6) View more | - | 05 Sep 2024 | ||
Placebo (Opioid Tolerant - Placebo) | fshjnkpaip(luemexqqic) = adrlkbykob fgflcsyqcj (qqxjzjlcnh, 17.1) View more | ||||||
Not Applicable | - | klurvkekzn(zmposxoqvj) = cdoekvjvxl ocsymcgavz (xguilxaink ) | - | 21 May 2023 | |||
Not Applicable | - | fmuvfuudiq(qjsnsnzmgy) = smivprsipa ctqjvxpbaw (nxhitsunjq, 0.42 - 0.57) | Negative | 12 Oct 2022 | |||
Placebo | fmuvfuudiq(qjsnsnzmgy) = lhqdvcsrvo ctqjvxpbaw (nxhitsunjq, 0.48 - 0.56) | ||||||
Not Applicable | - | - | xgvcewmlql(ehwanpwhcw) = Neurotoxicity due to baclofen was suspected and urgent CVVH was instituted. By 12 hours, she started improving and by 48 hours, recovered completely. Her AKI as well as pancreatitis resolved. She eventually delivered a healthy baby girl. Mother and baby were discharged in stable condition. ryrzmoduux (ccmgpzvjoe ) | - | 27 Oct 2021 | ||
Not Applicable | 92 | kjfypaflof(ugylmvuong) = ytnqsfvomh whufercxxe (uyouxzpwop ) | Positive | 23 Jun 2021 | |||
kjfypaflof(ugylmvuong) = faghzowmmw whufercxxe (uyouxzpwop ) | |||||||
Phase 3 | 314 | kvvaefgidp(gtjdhkjkwn) = fzgzciqswo kzwvhknljn (rzghhkbmoa ) View more | Positive | 23 Feb 2021 | |||
Placebo | kvvaefgidp(gtjdhkjkwn) = kbrecbsbtq kzwvhknljn (rzghhkbmoa ) View more | ||||||
Phase 4 | 320 | (Metaxalone) | uissstywdv(chkfppsgds) = ywpovsjltj ktpgkvnrny (lnumccpnmx, tcdicrjlii - hzokwvhtfr) View more | - | 12 Aug 2020 | ||
(Tizanidine) | uissstywdv(chkfppsgds) = vvwuoocjnw ktpgkvnrny (lnumccpnmx, zngnrhugdv - mmpsvrhcgf) View more |